Clinical trials: Esomeprazole
NSAIDs, Upper GI Symptoms
Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs
This study was a randomised, double-blind, parallel-group and placebo controlled study comparing the efficacy of esomeprazole 40 mg orally qd vs placebo and esomeprazole 20 mg orally qd vs placebo when given to patients on…
- Trial name
- NCT00241527
- Testing
- Esomeprazole
- Where
- 130 sites in United States, Australia and 9 more
- Volunteers
- 556 people
- Sponsor
- AstraZeneca
GERD
Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs
This study was a multicentre, double-blind, randomised, placebo-controlled parallel group study consisting of 4 visits over a period of 6 months.
- Trial name
- NCT00241514
- Testing
- Esomeprazole
- Where
- 113 sites in United States, Belgium and 4 more
- Volunteers
- 334 people
- Sponsor
- AstraZeneca
Juvenile Idiopathic Arthritis (JIA)
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month study of the safety of VIMOVO in adolescents aged 12 to 16 years with JIA.
- Trial name
- NCT01544114
- Testing
- VIMOVO 250/20, VIMOVO 375/20, VIMOVO 500/20
- Where
- 17 sites in United States
- Volunteers
- 46 people
- Sponsor
- Amgen
Symptomatic Gastroesophageal Reflux Disease (sGERD)
A Multicenter, Randomized, Double-Blind Parallel-Group, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg Once Daily to Placebo qd for the Resolution of Upper Abdominal Pain in Patients With Symptomatic Gastroesophageal Reflux Disease (sGERD)
This study compares 4 weeks of treatment with Esomeprazole 20 mg once daily to Placebo in the treatment of Upper Abdominal Pain in patients with Symptomatic Gastroesophageal Reflux Disease (sGERD)
- Trial name
- NCT00626535
- Testing
- Esomeprazole
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Healthy Volunteers, Bioequivalence
A Bioequivalence Study to Compare VIMOVO Manufactured at AstraZenca AB to VIMOVO Manufactured by Patheon Pharmaceuticals and Marketed Enteric-coated Naproxen Formulation
The primary purpose is to demonstrate the bioequivalence of naproxen administered as VIMOVO manufactured at a new facility in Sweden (AstraZeneca) to that of naproxen administered as VIMOVO manufactured in the USA (Patheon) and…
- Trial name
- NCT01331993
- Testing
- VIMOVO (AstraZeneca), VIMOVO (Patheon), Marketed enteric-coated naproxen formulation
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Pharmacokinetics of Isavuconazole, Healthy Subjects
A Study to Evaluate the Effect of Multiple Doses of Esomeprazole on the Pharmacokinetics of Isavuconazole
The purpose of this study is to assess the effect of multiple doses of esomeprazole on the pharmacokinetics of isavuconazole. In addition, safety and tolerability of isavuconazole alone and in combination with esomeprazole will…
- Trial name
- NCT02128893
- Testing
- Isavuconazole, Esomeprazole
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Global Development, Inc.
Gastroesophageal Reflux
Open, Randomised, Multi-center Study of on Demand Versus Continuous Esomeprazole Treatment in Patient With GERD
The purpose of this study is to compare on demand with continuous treatment of endoscopy negative subjects with gastroesophageal reflux disease (GERD), with esomeprazole 20-mg once daily, with regards to willingness to continue…
- Trial name
- NEED (NCT02670642)
- Testing
- Esomeprazole
- Where
- 60 sites in Austria, France and 3 more
- Volunteers
- 877 people
- Sponsor
- AstraZeneca
Healthy
Drug Drug Interaction Study Of Crizotinib With Esomeprazole.
This is an open-label, randomized, cross-over, single dose study in healthy volunteers to evaluate the potential effect of esomeprazole, a proton pump inhibitor, on the pharmacokinetics of crizotinib.
- Trial name
- NCT01549574
- Testing
- crizotinib, esomeprazole
- Where
- Belgium
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
ECL-cell Hyperplasia, Parietal-cell Hyperplasia
Effect of Netazepide on Omeprazole-induced Changes in Chromogranin A and Gastrin
Hypergastrinaemia induced by proton pump inhibitor (PPI) treatment is reported to cause ECL-cell and parietal-cell hyperplasia, and rebound hyperacidity and dyspepsia after PPI withdrawal.
- Conditions
- ECL-cell Hyperplasia, Parietal-cell Hyperplasia, Rebound Hyperacidity, Dyspepsia
- Trial name
- NCT02620696
- Testing
- netazepide
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Trio Medicines Ltd.
GERD
Clinical Trial to Evaluate the Safety and Efficacy of JP-1366 in Patients With Erosive Gastroesophageal Reflux Disease
Clinical trial to evaluate the safety and efficacy of JP-1366 in patients with erosive gastroesophageal reflux disease
- Trial name
- NCT04282954
- Testing
- JP-1366, Esomeprazole 40mg
- Where
- South Korea
- Volunteers
- 188 people
- Sponsor
- Onconic Therapeutics Inc.
Gastroesophageal Reflux, Heartburn
HEARD (Long Term) Study - Histology of the Esophagus in Acid-Related Disease
Determine if different levels of acid-suppression with esomeprazole for 6 months on chosen histological markers of esophageal epithelial acid-related disease in patients with upper GI symptoms.
- Conditions
- Gastroesophageal Reflux, Heartburn, Dyspepsia
- Trial name
- NCT00243724
- Testing
- Esomeprazole
- Where
- 10 sites in Canada
- Volunteers
- 350 people
- Sponsor
- AstraZeneca
Helicobacter Pylori Eradication
Effect of Probiotics on Helicobacter Pylori Eradication
The purpose of this clinical trial is to evaluate the clinical efficacy of Bifidobacterium quadruple live bacteria tablets (Si Lian Kang) on reducing the incidence rate of adverse reactions of Helicobacter pylori quadruple…
- Trial name
- NCT04034641
- Testing
- Bifidobacterium tetrad live bacteria tablet plus Helicobacter pylori quadruple eradication therapy
- Where
- 2 sites in China
- Volunteers
- 238 people
- Sponsor
- Hangzhou Grand Biologic Pharmaceutical, Inc.
Gastroesophageal Reflux Disease (GERD), Erosive Esophagitis
Esomeprazole for Treatment of GERD in Pediatric Patients
To look at the safety and improvement in symptoms of a once a day dosing of esomeprazole in children 1 to 11 years old with inflammation of their esophagus or food pipe ("esophagitis") caused by gastroesophageal reflux disease…
- Conditions
- Gastroesophageal Reflux Disease (GERD), Erosive Esophagitis, Non-erosive Esophagitis
- Trial name
- NCT00228527
- Testing
- Esomeprazole (Nexium)
- Where
- 36 sites in United States, Belgium and 2 more
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease, GERD
To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole
Administration of esomeprazole 20 mg to subjects who still had heartburn after receiving rabeprazole 10 mg once daily for at least 4 weeks will result in statistically significant improvement of heartburn after 8-week treatment.
- Conditions
- Gastroesophageal Reflux Disease, GERD, Reflux Esophagitis
- Trial name
- NCT01397084
- Testing
- esomeprazole 20 mg
- Volunteers
- 107 people
- Sponsor
- AstraZeneca
Gastrointestinal Disease, Signs and Symptoms, Digestive
Nexium Dyspepsia/AST
The aim is to evaluate if the resolution of upper abdominal symptoms (pain or burning) during an acid suppressive test trial of esomprazole given daily for 7 days predicts symptoms resolution at the end of a subsequent treatment…
- Conditions
- Gastrointestinal Disease, Signs and Symptoms, Digestive, Dyspepsia
- Trial name
- NCT00251992
- Testing
- Esomeprazole
- Where
- 183 sites in Austria, Belgium and 11 more
- Volunteers
- 1,200 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients
This study is designed to evaluate the efficacy and tolerability of ilaprazole relative to that of esomeprazole in healing erosive esophagitis and resolving accompanying symptoms of GERD.
- Trial name
- NCT01107938
- Testing
- 10 mg ilaprazole, 15 mg ilaprazole, 40 mg esomeprazole
- Volunteers
- 330 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
Acute and Chronic Inflammation, Dyspepsia
Evaluation of Two Therapies for the Treatment of Osteoarticular Inflammation in Dyspeptic Patients
The purpose of this study is to evaluate the safety of an association with one anti-inflammatory and one gastroprotective agent compared to the one anti-inflammatory and one gastroprotective agent in patients with acute or…
- Trial name
- NCT01670552
- Testing
- Nimesulide + Pantoprazole, Naproxen + Esomeprazole
- Where
- Brazil
- Volunteers
- 490 people
- Sponsor
- EMS
Repeatedly Recurring Esophagitis, Relapsing Reflux Esophagitis
Nexium Capsules RE Maintenance Specific Clinical Experience Investigation
The purpose of this study is to collect following data in patients given Nexium capsule (Nexium) in usual post-marketing use as the maintenance therapy for repeatedly recurring/relapsing reflux oesophagitis.
- Trial name
- NCT01562639
- Where
- 46 sites in Japan
- Volunteers
- 647 people
- Sponsor
- AstraZeneca
Healthy
Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of YH4808 After Oral Administration in Healthy Male Subjects
First in human study
- Trial name
- NCT01007019
- Testing
- YH4808 30mg, YH4808 50mg, YH4808 100mg
- Where
- South Korea
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Bioequivalence Study
Bioequivalence Study Comparing D961H Sachet and D961H Capsule in Japanese Healthy Male Subjects
This study is to investigate whether D961H sachet 20 mg is bioequivalent to D961H HPMC capsule 20 mg following repeated oral doses, and to evaluate the safety and tolerability of these two formulations in healthy male Japanese…
- Trial name
- NCT01595425
- Testing
- D961H Sachet 20 mg, D961H HPMC capsule 20 mg
- Where
- Japan
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- AstraZeneca